Jun 2026 (Q2 FY26) — Aug 6, 2026
Scholar Rock Q2 FY26 — Apitegromab BLA Progresses with Dual Fill/Finish Paths Towards September 30 PDUFA
Read the full callScholar Rock (SRRK) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Scholar Rock earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -110 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
13 of 14 judged targets kept · 5 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Commercial supply availability from second fill/finish facility | Have ample commercial apitegromab supply available from the second fill/finish facility in early Q3 2026, ahead of the September 30 PDUFA date | Mar 2026 | We now have more vials available from this facility than we do from Catalent Indiana. | Achieved |
| EU (EMA) marketing authorization decision | EU (EMA) marketing authorization decision on apitegromab, advancing toward approval in 2026 | Mar 2025 | we look forward to providing updated guidance on the potential timing of a CHMP opinion upon alignment with the European regulators. | Diluted |
| BLA resubmission and U.S. launch of apitegromab following approval | Resubmit BLA and complete U.S. launch of apitegromab, following FDA approval, in 2026 | Sep 2025 | we are very pleased that the apitegromab BLA continues to progress through FDA review with 2 independent paths to approval, and we remain on track for a decision by the September 30 PDUFA date. | On Track |
1 of Scholar Rock Holding Corp's 19 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 16 more targets are in the full ledger.
Claimed
- Ended Q2 FY26 with a strong cash position of $492 million in cash, cash equivalents, and marketable securities.
- Apitegromab BLA review progressing well with two independent paths to approval (Catalent Indiana and second fill/finish facility) ahead of September 30 PDUFA date.
- Initiated Phase II FORGE study for apitegromab in FSHD, addressing a significant unmet need.
- Robust enrollment in Phase II OPAL study evaluating apitegromab in infants and toddlers with SMA.
- Commercial organization is launch-ready in the U.S. and advancing preparations in Europe for apitegromab.
Qualified
- FDA inspection classification for Catalent Indiana fill/finish facility is still pending, having drifted beyond the 90-day guidance period.
- European MAA approval for apitegromab is dependent on FDA clearance of Catalent Indiana, with potential timing updates pending EMA alignment.
- Anticipate prior authorization and potential initial denials for apitegromab reimbursement in the U.S., leading to an average time from prescription to infusion greater than 60 days during the first 6 months post-launch.
Price
$40.24 +0.85% · +$0.34
Performance +44.0% 1Y
1Y: $27.94 on 17 Oct 2025 → $40.24. High $60.04 (26 Aug 2026), low $27.92 (20 Oct 2025).
- Previous close
- $39.9
- 52-week range
- $27.92 – $60.04
- One year
- +44.13%
Overview
- Symbol
- SRRK
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
13 of 14 judged targets kept · 5 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Commercial supply availability from second fill/finish facility | Have ample commercial apitegromab supply available from the second fill/finish facility in early Q3 2026, ahead of the September 30 PDUFA date | Mar 2026 | We now have more vials available from this facility than we do from Catalent Indiana. | Achieved |
| EU (EMA) marketing authorization decision | EU (EMA) marketing authorization decision on apitegromab, advancing toward approval in 2026 | Mar 2025 | we look forward to providing updated guidance on the potential timing of a CHMP opinion upon alignment with the European regulators. | Diluted |
| BLA resubmission and U.S. launch of apitegromab following approval | Resubmit BLA and complete U.S. launch of apitegromab, following FDA approval, in 2026 | Sep 2025 | we are very pleased that the apitegromab BLA continues to progress through FDA review with 2 independent paths to approval, and we remain on track for a decision by the September 30 PDUFA date. | On Track |
Claimed
- Ended Q2 FY26 with a strong cash position of $492 million in cash, cash equivalents, and marketable securities.
- Apitegromab BLA review progressing well with two independent paths to approval (Catalent Indiana and second fill/finish facility) ahead of September 30 PDUFA date.
- Initiated Phase II FORGE study for apitegromab in FSHD, addressing a significant unmet need.
- Robust enrollment in Phase II OPAL study evaluating apitegromab in infants and toddlers with SMA.
- Commercial organization is launch-ready in the U.S. and advancing preparations in Europe for apitegromab.
Qualified
- FDA inspection classification for Catalent Indiana fill/finish facility is still pending, having drifted beyond the 90-day guidance period.
- European MAA approval for apitegromab is dependent on FDA clearance of Catalent Indiana, with potential timing updates pending EMA alignment.
- Anticipate prior authorization and potential initial denials for apitegromab reimbursement in the U.S., leading to an average time from prescription to infusion greater than 60 days during the first 6 months post-launch.
The full ledger
Open Scholar Rock Holding Corp’s full ledger
A free account opens 5 company ledgers a month. All 19 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Scholar Rock Q1 FY26 — Apitegromab BLA Accepted with Dual Fill-Finish Facilities
Read the full callDec 2025 (Q4 FY25) — Mar 3, 2026
Scholar Rock Q4 FY25 — Apitegromab Regulatory Progress and Pipeline Advancement
Read the full callEvery analysed call
Scholar Rock earnings calls (SRRK)
Financials
What the filings say
Net profit, year on year: 0% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | — | — | — | — | — | 0 | 0 | — |
| Operating profit | -65 | -69 | -77 | -112 | -104 | -92 | -102 | -109 |
| Other income | 0 | 3 | 2 | 2 | 1 | 1 | -3 | -1 |
| Interest | 2 | 2 | 2 | 1 | 1 | 3 | 2 | 5 |
| Net profit | -64 | -66 | -75 | -110 | -102 | -91 | -106 | -110 |
| EPS ($ per share) | -0.66 | — | -0.67 | -0.98 | -0.90 | — | -0.83 | -0.84 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -107 | -158 | -244 | -376 | -511 | -676 | -923 | -1,301 |
| Total liabilities | 75 | 83 | 128 | 132 | 98 | 86 | 106 | 159 |
| Fixed assets | 3 | 4 | 8 | 10 | 7 | 5 | 3 | 2 |
| Investments | 61 | 121 | 181 | 40 | 212 | 178 | 259 | 44 |
| Total assets | 181 | 196 | 388 | 304 | 358 | 311 | 475 | 404 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 25 | -63 | -60 | -127 | -133 | -145 | -201 | -300 |
| Cash from investing | -60 | -62 | -63 | 134 | -172 | 41 | -76 | 219 |
| Cash from financing | 94 | 49 | 248 | 45 | 195 | 103 | 353 | 228 |
| Net cash flow | 59 | -76 | 124 | 52 | -110 | -2 | 76 | — |
| Capital expenditure | -1 | -3 | -4 | -5 | -1 | -0 | -0 | -1 |
| Free cash flow | 23 | -66 | -64 | -132 | -134 | -145 | -201 | -301 |
Insider filings
73 filings between Dec 4, 2025 and Sep 24, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$19.44M
38 sales by 13 insiders
58% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 15
- Award — granted as compensation
- 16
- Option exercise — converted options into shares
Also filed: 2 gifts, 2 option exercises.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Qatanani Mo | — | $8.60M | Feb 23, 2026 |
| Hallal David | — | $3.97M | Apr 16, 2026 |
| Vaishnaw Akshay | — | $1.48M | Apr 16, 2026 |
| Sinha Vikas | — | $1.23M | Apr 16, 2026 |
| Woods Keith | — | $1.22M | Apr 16, 2026 |
| Ho Junlin | — | $802.3K | Feb 17, 2026 |
| Parlavecchio Caryn | — | $713.9K | Feb 17, 2026 |
| Marantz Jing L. | — | $451.3K | Feb 17, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 24, 2026 | Woods Keith Chief Operating Officer | Gift | 48,034 | $0 |
| Sep 21, 2026 | Hallal David Chief Executive Officer | Gift | 36,652 | $0 |
| Jul 1, 2026 | Gilman Michael Director | Sale 10b5-1 plan | 1,155 | $62.6K |
| Jul 1, 2026 | Reed Joshua Director | Sale 10b5-1 plan | 948 | $51.5K |
| Jul 1, 2026 | FLIER JEFFREY S. Director | Sale 10b5-1 plan | 1,470 | $79.7K |
| Jul 1, 2026 | Peng Katie Director | Sale 10b5-1 plan | 2,437 | $132.2K |
| Jul 1, 2026 | FLIER JEFFREY S. Director | Sale 10b5-1 plan | 15 | $823 |
| Jul 1, 2026 | Gilman Michael Director | Sale 10b5-1 plan | 1,346 | $72.1K |
| Jul 1, 2026 | Gilman Michael Director | Sale 10b5-1 plan | 43 | $2.4K |
| Jul 1, 2026 | Reed Joshua Director | Sale 10b5-1 plan | 2,105 | $112.6K |
| Jul 1, 2026 | Burow Kristina Director | Sale 10b5-1 plan | 2,105 | $112.6K |
| Jul 1, 2026 | Burow Kristina Director | Sale 10b5-1 plan | 948 | $51.5K |
| Jul 1, 2026 | Peng Katie Director | Sale 10b5-1 plan | 2,988 | $160.0K |
| Jul 1, 2026 | Peng Katie Director | Sale 10b5-1 plan | 21 | $1.2K |
| Jul 1, 2026 | FLIER JEFFREY S. Director | Sale 10b5-1 plan | 1,568 | $83.9K |
| Jun 4, 2026 | Peng Katie Director | Award | 6,839 | $0 |
| Jun 4, 2026 | Gilman Michael Director | Award | 6,839 | $0 |
| Jun 4, 2026 | FLIER JEFFREY S. Director | Award | 6,839 | $0 |
| Jun 4, 2026 | Reed Joshua Director | Award | 6,839 | $0 |
| Jun 4, 2026 | AKKARAJU SRINIVAS Director | Award | 6,839 | $0 |
| Jun 4, 2026 | Brudnick Richard Director | Award | 6,839 | $0 |
| Jun 4, 2026 | Burow Kristina Director | Award | 6,839 | $0 |
| Apr 23, 2026 | Burow Kristina Director | Option exercise | 18,000 | $150.5K |
| Apr 23, 2026 | Burow Kristina Director | Option exercise | 7,800 | $208.9K |
| Apr 23, 2026 | Burow Kristina Director | Option exercise | 36,000 | $328.0K |
| Apr 23, 2026 | Burow Kristina Director | Option exercise | 28,000 | $133.0K |
| Apr 16, 2026 | Hallal David Chief Executive Officer | Sale | 30,615 | $1.52M |
| Apr 16, 2026 | Woods Keith Chief Operating Officer | Sale | 10,220 | $506.7K |
| Apr 16, 2026 | Vaishnaw Akshay President of R&D | Sale | 12,246 | $607.1K |
| Apr 16, 2026 | Sinha Vikas Chief Financial Officer | Sale | 10,410 | $516.1K |
| Feb 23, 2026 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 plan | 200 | $9.7K |
| Feb 23, 2026 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 plan | 857 | $41.0K |
| Feb 23, 2026 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 plan | 7,427 | $348.6K |
| Feb 17, 2026 | Marantz Jing L. CHIEF MEDICAL OFFICER | Sale | 4,157 | $193.4K |
| Feb 17, 2026 | Parlavecchio Caryn CHRO | Sale | 9,035 | $420.4K |
| Feb 17, 2026 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale | 7,989 | $371.7K |
| Feb 17, 2026 | Ho Junlin GENERAL COUNSEL | Sale | 9,580 | $445.7K |
| Feb 9, 2026 | Woods Keith Chief Operating Officer | Award | 47,021 | $0 |
| Feb 9, 2026 | Parlavecchio Caryn Chief Human Resources Officer | Award | 29,258 | $0 |
| Feb 9, 2026 | Vaishnaw Akshay President of R&D | Award | 47,021 | $0 |
| Feb 9, 2026 | Sinha Vikas Chief Financial Officer | Award | 47,021 | $0 |
| Feb 9, 2026 | Qatanani Mo Chief Scientific Officer | Award | 29,258 | $0 |
| Feb 9, 2026 | Marantz Jing L. Chief Medical Officer | Award | 34,482 | $0 |
| Feb 9, 2026 | Ho Junlin General Counsel | Award | 36,572 | $0 |
| Feb 9, 2026 | Hallal David Chief Executive Officer | Award | 128,004 | $0 |
| Jan 22, 2026 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 plan | 12,779 | $598.7K |
| Jan 22, 2026 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 plan | 2,119 | $97.2K |
| Jan 16, 2026 | Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sale | 8,406 | $373.9K |
| Jan 16, 2026 | Parlavecchio Caryn CHRO | Sale | 6,600 | $293.6K |
| Jan 16, 2026 | Ho Junlin GENERAL COUNSEL | Sale | 8,016 | $356.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Scholar Rock Holding Corp
Free account. Everything above stays public.
Write why you follow Scholar Rock Holding Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading